INBRAIN Neuroelectronics, Mayo Clinic Team Up on Graphene-Based BCI

INBRAIN Neuroelectronics has entered into a know-how collaboration agreement with Mayo Clinic to accelerate the development and commercialization of INBRAIN’s precision brain-computer interface therapeutics (BCI-Tx) for patients with unmet needs in neurological-related disorders.

As part of the collaboration, INBRAIN and Mayo Clinic experts will pool their talents to engage in hands-on evaluation of INBRAIN’s investigational BCI-Tx platform in IRB-approved settings with the goal of accelerating, high-quality evidence generation.

“Our goal is to translate the unique performance of graphene and AI to deliver benefits for patients and clinicians,” INBRAIN Neuroelectronics Co-Founder/CEO Carolina Aguilar said. “With Mayo Clinic’s clinical know-how, alongside other U.S. and European centers, we seek to validate our platform in real-world workflows, accelerate evidence generation, and move responsibly toward patient-focused BCI therapeutics.”

INBRAIN is also forming a U.S. subsidiary to collaborate with U.S. academic centers, and locations are set to open in Boston and the West Coast; the company, however, will maintain its global headquarters and R&D in Barcelona, Spain. The initial Boston office will serve as a hub for U.S.-based clinical trials and build the foundation for commercialization and therapeutic expansion of its BCI-Tx beyond Parkinson’s disease. INBRAIN is also advancing scalable manufacturing processes for its graphene-based BCI to enable broader clinical and commercial adoption worldwide.

INBRAIN has raised $124 million in financing to date from a global syndicate of medtech and deeptech investors, including Aliath Bioventures, Asabys Partners, CDTI, Catalan Government (Avançsa & ICF), FondICO, Graybella Capital, IMECXpand, Mayo Clinic, the European Innovation Council, Truventuro ,and Vsquared Ventures.

Mayo Clinic has a financial interest in INBRAIN’s technology and will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.

INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world’s first graphene-based brain-computer interface (BCI) therapeutics platform. Its technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, the firm’s artificial intelligence-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and its subsidiary INNERVIA Bioelectronics, INBRAIN is extending creative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics.